Location History:
- Tel Aviv, IL (1999)
- Dallas, TX (US) (1992 - 2011)
Company Filing History:
7 out of 5,450 
1 out of 832,843 Years Active: 1992-2011
Title: Yuval Reiss: Innovator in Farnesyl Transferase Inhibition
Introduction
Yuval Reiss is a prominent inventor based in Dallas, TX (US). He has made significant contributions to the field of biochemistry, particularly in the development of methods for identifying inhibitors of farnesyl transferase enzymes. With a total of 8 patents to his name, Reiss has established himself as a key figure in the fight against cancer-related proteins.
Latest Patents
Reiss's latest patents focus on methods for identifying farnesyl transferase inhibitors. These patents disclose methods and compositions for the identification of inhibitors of farnesyl protein transferases, which are enzymes involved in the farnesylation of various cellular proteins, including cancer-related ras proteins such as p21. One of the farnesyl protein transferases disclosed exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. The patents also detail methods for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for identifying possible anticancer agents that inhibit the enzyme and thereby prevent the expression of proteins such as p21. Additionally, the patents disclose a family of compounds that act either as false substrates for the enzyme or as pure inhibitors, which can be employed for inhibition of the enzyme. The most potent inhibitors are those in which phenylalanine occurs at the third position of a tetrapeptide whose amino terminus is cysteine.
Career Highlights
Throughout his career, Yuval Reiss has worked with notable institutions, including the University of Texas System. His work has significantly advanced the understanding of farnesyl transferase enzymes and their role in cancer biology.
Collaborations
Reiss has collaborated with esteemed colleagues such as Michael S. Brown and Joseph L. Goldstein, further enhancing the impact of his research in the scientific community.
Conclusion
Yuval Reiss is a distinguished inventor whose work on farnesyl transferase inhibitors has the potential to contribute significantly to cancer treatment. His innovative approaches and collaborations continue to inspire advancements in biochemistry and medicine.